Fluticasone furoate for the treatment of childhood asthma

Hanna Phan, Mark A. Brown

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Inhaled corticosteroids offer substantial benefit in controlling symptoms for the vast majority of children with asthma. However, poor adherence to therapy is very common, especially among older children and adolescents as they transition to self-management of their disease. The introduction of once-daily inhaled fluticasone furoate, either alone or in combination with the long-acting β-agonist, vilanterol, simplifies chronic asthma therapy and may improve adherence and as a result, outcomes in this vulnerable population. Opportunities exist for additional study of this agent in younger children, particularly with regard to safety and growth suppression. This review provides an overview of the pharmacology, safety and efficacy data regarding use of fluticasone furoate in the treatment of childhood asthma.

Original languageEnglish (US)
Pages (from-to)391-404
Number of pages14
JournalExpert Review of Respiratory Medicine
Issue number4
StatePublished - Aug 1 2015


  • asthma
  • efficacy
  • fluticasone furoate
  • pediatric
  • pharmacodynamics
  • pharmacokinetics
  • safety

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Fluticasone furoate for the treatment of childhood asthma'. Together they form a unique fingerprint.

Cite this